Georges Te Natsoulis

US Patent:

6365403, Apr 2, 2002

Filed:

Nov 29, 1999

Appl. No.:

09/449581

Inventors:

Georges Natsoulis - San Francisco CA
Gary Kurtzman - Villanova PA
Peter Colosi - Alameda CA

Assignee:

Avigen, Inc. - Alameda CA

International Classification:

C12N 510

US Classification:

435325, 435369, 435366, 536 231, 536 2372, 536 241

Abstract:

The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (ârAAVâ) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

US Patent:

7396645, Jul 8, 2008

Filed:

Dec 16, 2003

Appl. No.:

10/738014

Inventors:

Georges Natsoulis - Kensington CA, US
Cecelia Pearson - Emerald Hills CA, US
Stuart Tugendreich - Mountain View CA, US
Michael Furness - Ely Cambridgeshire, GB

Assignee:

Entelos, Inc. - Foster City CA

International Classification:

C12Q 1/68

US Classification:

435 6, 536 2431

Abstract:

The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholestasis in a subject. The invention also includes a Cholestasis signature database as well as the method of deriving such database.

US Patent:

7422854, Sep 9, 2008

Filed:

Dec 18, 2003

Appl. No.:

10/741509

Inventors:

Georges Natsoulis - Kensington CA, US
Stuart Tugendreich - Mountain View CA, US
Cecelia Pearson - Emerald Hills CA, US
Michael Furness - Ely, GB

Assignee:

Entelos, Inc. - Foster City CA

International Classification:

C12Q 1/68

US Classification:

435 6, 536 2431

Abstract:

The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholesterol reduction in a subject. The invention also includes a cholesterol reduction signature as well as the method of deriving such signature.

US Patent:

7519519, Apr 14, 2009

Filed:

Dec 18, 2003

Appl. No.:

10/741506

Inventors:

Barrett P. Eynon - Menlo Park CA, US
Georges Natsoulis - Kensington CA, US
Kurt Jarnigan - San Meteo CA, US

Assignee:

Entelos, Inc. - Foster City CA

International Classification:

G06F 17/10
G06F 7/60

US Classification:

703 2, 702 19, 702 23, 435 6, 436 63

Abstract:

Disclosed is a method for predicting the biological activity of a compound by the similarity of its drug signature score to the scores of a plurality of known drug signatures.

US Patent:

7588892, Sep 15, 2009

Filed:

Jul 18, 2005

Appl. No.:

11/184272

Inventors:

Georges Natsoulis - Kensington CA, US
Mark Fielden - Moutain View CA, US
Kurt Jarnagin - San Mateo CA, US
Kyle Kolaja - San Mateo CA, US

Assignee:

Entelos, Inc. - Foster City CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

US Patent:

7778782, Aug 17, 2010

Filed:

Dec 16, 2003

Appl. No.:

10/738022

Inventors:

Cecelia Pearson - Emerald Hills CA, US
Michael Furness - Ely, GB
Stuart Tugendreich - Mountain View CA, US
Georges Natsoulis - Kensington CA, US

Assignee:

Entelos, Inc. - Foster City CA

International Classification:

G06F 19/00

US Classification:

702 27

Abstract:

The present invention includes methods and apparatus for use in rapid testing for and prediction of a PPARα response (i. e. a response similar to that of PPARα agonists). The invention includes a PPARα response signature comprising a set of twenty genes. The invention discloses methods whereby the differential expression of the genes of the PPARα response signature may be used to predict whether a compound will induce a PPARα response in a test subject.

US Patent:

20020115189, Aug 22, 2002

Filed:

Dec 18, 2001

Appl. No.:

10/026389

Inventors:

Georges Natsoulis - San Francisco CA, US
Gary Kurtzman - Villanova PA, US
Peter Colosi - Alameda CA, US

Assignee:

Avigen, Inc.

International Classification:

C12N007/00
C12N015/86
C12N005/00

US Classification:

435/235100, 435/325000, 435/456000

Abstract:

The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

US Patent:

20030180808, Sep 25, 2003

Filed:

Feb 28, 2003

Appl. No.:

10/378002

Inventors:

Georges Natsoulis - Kensington CA, US

International Classification:

G01N033/53
G01N033/567
G06F019/00
G01N033/48
G01N033/50
C12Q001/68

US Classification:

435/007100, 435/007200, 702/019000, 435/006000

Abstract:

Methods for deriving and using Group Signatures and Drug Signatures are provided, wherein Group Signatures comprise a plurality of genes, modulated expression of which is characteristic and specific of a group of related drug compounds, and wherein Drug Signatures comprise a plurality of genes, modulated expression of which is characteristic and specific for individual drug compounds.